ClinicalTrials.gg
CompletedNCT04380389Updated May 4, 2026Results posted

Accuracy of ScanWatch Pulse Oximeter With Profound Hypoxia

An interventional study of hypoxia in Oximetry, sponsored by Withings. Completed at 1 site in United States. Open to participants aged 18 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Withings · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
14
Allocation
Not applicable
Ages
18 Years to 49 Years
Sex
All
01

Study summary

Performance testing of pulse oximeters. The protocol involves brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained. The blood sample is analyzed for oxygen saturation with a gold standard bench CO-oximeter. This protocol is aligned with the latest ISO and FDA guidance documents for pulse oximeter testing.

02

Conditions studied

  • Oximetry
03

In context

Lead sponsor

Withings is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is male or female, aged ≥18 and \<50.
  • The subject is in good general health with no evidence of any medical problems.
  • The subject has both wrist circumferences between 14 and 22cm.
  • The subject has provided and is willing to comply with the study procedures.

Exclusion criteria

Exclusion Criteria:

  • The subject is obese (>30).
  • The subject has a known history of heart disease, lung disease, kidney or liver disease.
  • Diagnosis of asthma, sleep apnea, or use of CPAP.
  • Subject has diabetes.
  • Subject has a clotting disorder.
  • The subject a hemoglobinopathy or history of anemia, per subject report or the first blood sample that in the opinion of the investigator, would make them unsuitable for study participation.
  • The subject has any other serious systemic illness.
  • The subject is a current smoker.
  • The subject has piercings that may cause air leaks during the test
  • The subject has any injury, deformity, or abnormality at the sensor sites that in the opinion of the investigators' would interfere with the sensors working correctly.
  • The subject has a history of fainting or vasovagal response.
  • The subject has a history of sensitivity to local anesthesia.
  • The subject has a diagnosis of Raynaud's disease.
  • The subject has unacceptable collateral circulation based on exam by the investigator (Allen's test).
  • The subject is pregnant, lactating or trying to get pregnant.
  • The subject is unable or unwilling to provide , or is unable or unwilling to comply with study procedures.
  • The subject has a resting heartrate over 120, Systolic BP is over 150, diastolic BP is over 90 or room air SpO2 is less than 94%.
  • The subject has carboxyhemoglobin over 3% as measured by Lab blood gas analysis.
  • The subject has any other condition, which in the opinion of the investigators' would make them unsuitable to participate.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Other
    profound hypoxia

    Diagnostic Test: hypoxia

Interventions

  • Diagnostic testhypoxia

    Brief stable arterial oxygen desaturation in healthy volunteers and sampling arterial blood when a stable level of hypoxia has been attained.

06

What researchers measure

Primary outcomes

  1. RMSE Compared to CO-oximetry

    Root Mean Squared Error between the functional blood oxygen saturation (SpO2) provided by the device under test and the arterial blood oxygen measured with the CO-oximeter.

    Time frame: 1 hour

07

Results

Posted May 4, 2026

Participant flow

First enrolment: 2020/03/11 Last subject completed: 2020/03/12 The study included eligible volunteers at UCSF. The investigators selected subjects, balanced in terms of gender, age, and skin pigmentation. Participation to the study was offered to the subjects until the target headcounts was reached.

Participant flow — Overall Study
MilestoneLeft vs Right Hand
Started14
Completed14
Not completed0

Outcome measures

PrimaryRMSE Compared to CO-oximetry

Root Mean Squared Error between the functional blood oxygen saturation (SpO2) provided by the device under test and the arterial blood oxygen measured with the CO-oximeter.

Time frame:
1 hour
Reported as:
Number · RMSE (%)
RMSE Compared to CO-oximetry
RMSE (%)Left BiasRight Bias
RMSE Compared to CO-oximetry2.973.00

Adverse events

Collected over On the day of the visit. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Left vs Right Hand0/14 (0%)0/14 (0%)0/14 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(year)Left vs Right Hand
Mean27.1 ± 3.9
Sex: Female, Male
Sex: Female, Male(Participants)Left vs Right Hand
Female6
Male8
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Left vs Right Hand
Skin tone
Skin tone(Participants)Left vs Right Hand
Fair skin tone4
Medium skin tone7
Dark skin tone3
BMI (kg/m²)
BMI (kg/m²)(kg.m-²)Left vs Right Hand
Mean23.4 ± 2.1
Height
Height(cm)Left vs Right Hand
Mean168.7 ± 9.8
Weight
Weight(kg)Left vs Right Hand
Mean66.6 ± 8.6
08

Study locations

1 site
  • Hypoxia Lab, UCSF
    San Francisco, California 94133, United States
09

References and documents

Publications

  • Kirszenblat R, Edouard P. Validation of the Withings ScanWatch as a Wrist-Worn Reflective Pulse Oximeter: Prospective Interventional Clinical Study. J Med Internet Res. 2021 Apr 26;23(4):e27503. doi: 10.2196/27503. PubMed 33857011 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04380389
Lead sponsor
Withings
Responsible party
Sponsor
First posted
May 8, 2020
Start date
Mar 11, 2020
Primary completion
Mar 12, 2020
Completion
Mar 12, 2020
Results posted
May 4, 2026
Last update
May 4, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion